<DOC>
	<DOCNO>NCT02369653</DOCNO>
	<brief_summary>The purpose study compare effect blood thin drug call Apixaban versus administration blood thin drug , prevent blood clot child leukemia lymphoma . Patients must receive chemotherapy ; include Pegylated L-Asparaginase central line ( catheter insert administration medication blood sample ) .</brief_summary>
	<brief_title>A Study Safety Effectiveness Apixaban Preventing Blood Clots Children With Leukemia Who Have Central Venous Catheter Are Treated With Pegylated ( PEG ) L-Asparaginase</brief_title>
	<detailed_description />
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Apixaban</mesh_term>
	<mesh_term>Anticoagulants</mesh_term>
	<mesh_term>Asparaginase</mesh_term>
	<criteria>For information regard BMS clinical trial participation , please visit www.BMSStudyConnect.com New diagnosis de novo ALL , lymphoma ( T B cell ) , mixedphenotype acute leukemia Planned induction chemotherapy corticosteroid , vincristine single dose multiple dos PEG Lasparaginase , without daunorubicin consistent Children 's Oncology Group ( COG ) ALL trial Functioning Central Venous Access Device Must able tolerate oral medication administer via Nasogastric tube ( NGT ) GT tube Males female , age 1 year ( 365 day ) &lt; 18 ( 17 year 364 day ) year . Platelet Counts â‰¥ 20000/microL Subjects schedule &gt; 3 Lumbar Punctures course treatment period Prior history document DVT PE past 3 month Known inherited bleeding disorder coagulopathy Major surgery [ exclude Central Venous Access Device ( CVAD ) replacement bone marrow aspiration nonopen biopsy ] within last 7 day prior enrollment may associate risk bleeding . Open biopsy consider major surgery . Uncontrolled severe hypertension enrollment . Severe hypertension define systolic diastolic blood pressure ( BP ) &gt; 5 mm Hg 95th percentile define National High Blood Pressure Education Program Working Group ( NHBPEP ) establish guideline definition normal elevate blood pressure child Extreme hyperleukocytosis , white blood cell ( WBC ) count 200 x 109/L ( 200,000/microL ) time enrollment Liver dysfunction manifest SGTP ( ALT ) &gt; 5X Upper limit normal ( ULN ) and/or Aspartate aminotransferase ( AST ) &gt; 5 X ULN and/or direct ( conjugate ) bilirubin &gt; 2X ULN Renal function &lt; 30 % normal age size determine Schwartz formula International normalized ratio ( INR ) &gt; 1.4 activate partial thromboplastin time ( aPTT ) &gt; 3 second upper limit normal age , within 1 week prior enrollment . History allergy apixaban Factor Xa inhibitor History significant adverse reaction major bleeding relate adverse reaction anticoagulant antiplatelet agent History significant drug allergy ( anaphylaxis hepatotoxicity Any investigational drug administer study</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>17 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Anticoagulation</keyword>
</DOC>